Christopher Cannon/LinkedIn
Oct 3, 2025, 11:50
Christopher Cannon on Evolocumab – Landmark Phase 3 Trial Shows Benefit in Those at High Risk of CV Events
Christopher Cannon, Cardiologist at Brigham and Women’s Hospital, Editor-in-Chief of Harvard Heart Letter, shared on LinkedIn:
”Late-breaking news!!!
PCSK9 inhibition with evolocumab shows benefit in those at high risk of CV events, (in addition to secondary prevention as shown in FOURIER)”
Read the full article here.
Article: Landmark Phase 3 Trial (Vesalius-CV) Meets Primary Endpoints in a Cardiovascular Primary Prevention Study of 12,000 Patients
Stay updated on the latest scientific breakthroughs with Hemostasis Today.
-
Nov 19, 2025, 18:03Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
-
Nov 19, 2025, 17:50Marilena Vrana Reflects on PPTA Europe’s Visits with Members and Stakeholders in 2025
-
Nov 19, 2025, 17:32Michael Makris Shares Insights from Global Forum Meeting of the WFH Meeting in Montreal
-
Nov 19, 2025, 17:14Yazan Abou Ismail Takes The Legacy Award from Qatar Foundation
-
Nov 19, 2025, 17:02Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
-
Nov 19, 2025, 16:34Ishita Singh Reflects on Haematocon 2025: A Reminder of Her Commitment to The Journey
-
Nov 19, 2025, 16:23Mehdi Kashani: I’m Really Excited to Share Schistosite.com
-
Nov 19, 2025, 16:09A ”Meow-cyte” from Melaku Abay Muluneh or Why Microscopy Never Gets Old!
-
Nov 19, 2025, 15:56Cuilan Li on her Contribution to a Cutting-Edge Project in Polycythemia Vera